Prevalence and Predictors of Spike Protein Antibodies in COVID-19 Vaccinated Individuals


About this study

The objectives of this study are to determine the prevalence of spike (S) protein antibodies in COVID-19 vaccinated individuals, to assess the role of age and gender in relation to the capacity of COVID-19 vaccinated individuals to develop S protein antibodies, and to identify microRNA (miRNA) in serum derived exosomes that correlates with S protein antibody development and determine how age and gender may affect the correlation B.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults 18 years or older.
  • Have received COVID-19 vaccine that involve the mRNA that encode the COVID-19 S protein.
  • Volunteers must have received all the doses required before enrollment.
  • At least a week must have passed from the last dose of the vaccine before a blood sample can be collected.

Exclusion Criteria:

  • Individuals who have had COVID infection are excluded.
  • Volunteers must not be taking immunosuppressive medications during and post vaccination period.
  • Volunteers must not have uncontrolled diabetes and should not have been diagnosed with immune deficiency diseases.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Abba Zubair, M.D., Ph.D.

Closed for enrollment

Contact information:

Terri Younger

(904) 953-2429

More information


Publications are currently not available

Mayo Clinic Footer